Datopotamab Deruxtecan Provides PFS Benefit in HR+/HER2– Breast Cancer

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.

Related Keywords

Boston ,Massachusetts ,United States ,Madrid ,Spain ,Aditya Bardia ,Ken Takeshita ,Daiichi Sankyo ,Susan Galbraith ,Astrazeneca ,Harvard Medical School ,Hospital Cancer Center ,Massachusetts General Hospital Cancer Center ,Breast Cancer ,Esmo Congress ,Conference ,Nct05104866 ,Tropion Breast01 Trial ,Datopotamab Deruxtecan ,